Related Experiment Video
Updated: May 15, 2026

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
Published on: August 25, 2014
Neurocognitive development of children born small for gestational age (SGA). An update
Beatriz Puga1, Paloma Gil, Antonio de Arriba
1Andrea Prader Foundation, IACS (Instituto de Ciencias de La Salud - Institute of Health Sciences), Government of Aragon.
Insights
Children born small for gestational age (SGA) face significant neurocognitive development risks. Catch-up growth offers some protection, but growth hormone therapy shows no benefit in improving outcomes.
Area of Science:
- Pediatric Endocrinology
- Neurodevelopmental Pediatrics
- Child Psychology
Background:
- Being born small for gestational age (SGA) is a recognized concern.
- Long-term neurocognitive outcomes for SGA children require further investigation.
- The impact of catch-up growth and growth hormone (GH) therapy on neurodevelopment is not fully elucidated.
Purpose of the Study:
- To confirm that being born SGA poses a significant risk for negative neurocognitive development.
- To evaluate the influence of catch-up growth status on neurocognitive outcomes in SGA children.
- To assess the efficacy of growth hormone (GH) therapy in mitigating neurocognitive deficits in SGA individuals.
Main Methods:
- Longitudinal follow-up of 233 SGA cases, with some assessed up to 11 times.
- Yearly neurocognitive assessments conducted by a single investigator.
- Categorization of participants into catch-up growth positive (catch-up +) and negative (catch-up -) groups.
- Analysis of IQ scores relative to standard deviations (SD).
Main Results:
- 25.8% of SGA children exhibited an IQ less than 2 SD below the mean.
- Children in the catch-up + group showed a lower incidence of low IQ (15%) compared to the catch-up - group (31.4%).
- Growth hormone (GH) therapy, regardless of initiation age (before or after 6 years), did not improve neurocognitive outcomes.
Conclusions:
- Being born SGA is a significant risk factor for impaired neurocognitive development.
- Catch-up growth may offer a protective effect against severe neurocognitive deficits in SGA children.
- Growth hormone therapy does not appear to enhance neurocognitive development in this SGA cohort.
Abstract:
The aim of the present study is to confirm that being born SGA is a serious risk for a negative neurocognitive development. 233 cases have been controlled yearly and longitudinally by the same investigator, some of them 11 times, showing 25,8 % an IQ less than 2 SD, being less affected the catch-up + group (15 %), compared to the catch-up - group (31,4 %). The GH therapy (n 64) started before the age of 6 (n 38) or after 6 (n 26), doesn't improve the negative outcome.
Related Concept Videos
Nature and Nurture
The Nativist Approach
Piaget's Stage 1 of Cognitive Development
Exploration...
Neurulation

